Abstract
essential. 8 As the need for rapid tumor profiling increases, it is epithelial differentiation antigen and believed to be present in most
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Monoclonal antibodies against EpCAM, MUC-1, HER-2,
111
EGFR and vimentin were used for the primary labeling of Figure 1 . Schematic of the detection and characterization study of CTC and metastatic tumor using magnetic nanoparticle labeling and quad-μNMR detection system. Peripheral blood (7 ml) and fine needle biopsy from the site of metastasis were obtained. Samples were labeled by incubating cells with primary antibodies followed by TCO-modified secondary antibodies (Step 1). Cells were then pelleted by centrifugation and resuspended directly with Tz-nanoparticles that selectively targeted TCO-antibodies (
Step 2). The process of labeling and targeting required 40 min. Cancer marker measurements were taken using the μNMR device to produce quantitative protein read-outs.
antigens. To enhance the labeling efficiency, TCO modification and 10% dimethylformamide at room temperature for 3 h.
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Unreacted TCO-NHS was subsequently washed using 2 ml of markers, treatment changes, death) within the study period. 7 CTC/ml, range 3-21 CTC/ml). (Table S1 ). 
Discussion

247
The overall goal of this study was to determine (1) whether 248 the nanotechnology-driven μNMR approach could be used for In its latest iteration, μ-NMR harnesses a cocktail approach to to study a single cancer type but rather sample a typical cohort of 
